Cycloastragenol (TA-65)
Cycloastragenol (TA-65) · also known as Cycloastragenol, TA-65, Triterpenoid saponin aglycone, Astragalus extract
In animal and cell studies, cycloastragenol can affect telomerase-related markers. Results from human randomized trials are inconsistent. In the low-dose group, telomere length in blood cells increased somewhat, but telomerase activity showed no significant difference between groups. Telomerase activation in humans has not been established.
Clinical uses and human evidence
Body weight and body fat
Inflammation markers (such as CRP)
Studies (2)
- Bawamia 2023 · Geroscience · RCT · n=90 — Activation of telomerase by TA-65 enhances immunity and reduces inflammation post myocardial infarction
- Fernandez 2018 · Curr Pharm Des · Randomized crossover trial · n=40 — TA-65, A Telomerase Activator improves Cardiovascular Markers in Patients with Metabolic Syndrome
Mechanisms of action
Mild telomerase reverse transcriptase (TERT) activation and telomere stabilization
Animal and cell studies suggest that cycloastragenol can affect TERT-related telomerase expression. In human randomized trials, mean telomere length in blood cells increased in the low-dose group, while the high-dose group did not reach statistical significance. Telomerase activity at 12 months did not differ significantly between groups, so telomerase activation in humans has not been established.
References (3)
- De Jesus et al. 2011 · Mouse study: TERT levels and short-telomere markers changed in some tissues
- Salvador et al. 2016 · Human randomized trial: mean telomere length in blood cells increased in the low-dose group; high-dose results did not reach significance
- Bawamia et al. 2023 · Human randomized trial: no significant between-group difference in telomerase activity at 12 months
Safety and drug interactions
Immune stimulation
Has immunomodulating effects. Each of these stimulates immune responses. They may counteract immunosuppressant drugs, and caution is also needed during active autoimmune disease.